AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103
15 sept. 2020 07h00 HE
|
Amryt Pharma Plc
AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103 DUBLIN, Ireland, and Boston MA, September 15 2020, Amryt (Nasdaq: AMYT,...
Amryt Pharma Plc - Full Year 2019 RESULTS
11 mai 2020 07h00 HE
|
Amryt Pharma Plc
May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) FY 2019 RESULTS Transformational year of performance and growth for AmrytAegerion integration...
Amryt Pharma Plc - Q1 2020 RESULTS
11 mai 2020 07h00 HE
|
Amryt Pharma Plc
May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) Q1 2020 RESULTS $44.6M unaudited Q1 revenues representing a 30% increase on unaudited combined revenues of...